Stocks of BIND Therapeutics (NASDAQ:BIND) rallied by 0.5% during the past week but lost 1.98% on a 4-week basis. The company has outperformed the S&P 500 by 1.71% in the past week but underperformed the index by 2.87% in the last 4 weeks.
BIND Therapeutics (NASDAQ:BIND): The stock opened at $0.43 on Friday but the bulls could not build on the opening and the stock topped out at $0.53 for the day. The stock traded down to $0.38 during the day, due to lack of any buying support eventually closed down at $0.40 with a loss of -4.29% for the day. The stock had closed at $0.42 on the previous day. The total traded volume was 2,183,457 shares.
The company shares have dropped -93.17% from its 1 Year high price. On Jun 23, 2015, the shares registered one year high at $6.22 and the one year low was seen on May 17, 2016. The 50-Day Moving Average price is $0.45 and the 200 Day Moving Average price is recorded at $1.64.
Many analysts have stated their opinion on the company shares. Equity Analysts at the Brokerage Firm, Cowen & Company, downgrades their rating on the shares of BIND Therapeutics (NASDAQ:BIND). Cowen & Company has a Market Perform rating on the shares. Previously, the analysts had a Outperform rating on the shares. The rating by the firm was issued on April 7, 2016. Currently the company Insiders own 11% of BIND Therapeutics shares according to the proxy statements. Institutional Investors own 17.15% of BIND Therapeutics shares.
BIND Therapeutics, Inc. is a clinical-stage nano-medicine platform company. The Company is engaged in developing a pipeline of Accurins. The Company utilizes its Medicinal Nano-engineering platform to develop a pipeline of Accurins in oncology. The Companys products include BIND-014 and BIND-510. The Companys lead drug candidate BIND-014 is a prostate-specific membrane antigen (PSMA)-targeted Accurin that contains docetaxel, a clinically validated cancer chemotherapy drug. PSMA is a clinically validated tumor marker expressed on prostate cancer cells and the blood vessels of many types of non-prostate solid tumors. It has completed a Phase I clinical trial evaluating BIND-014 in patients with advanced and metastatic solid tumors. The Companys product candidate BIND-510 is also a PSMA-targeted Accurin containing vincristine. BIND-510 is designed to concentrate high levels of vincristine in tumors while limiting exposure to healthy tissue.